Percutaneous cryoablation of pulmonary metastases from colorectal cancer

• Published in: PloS one Vol. 6; no. 11; p. e27086
• Main Authors: Yamauchi, Yoshikane, Izumi, Yotaro, Kawamura, Masafumi, Nakatsuka, Seishi, Yashiro, Hideki, Tsukada, Norimasa, Inoue, Masanori, Asakura, Keisuke, Nomori, Hiroaki
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 09.11.2011; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Aged, 80 and over; Biology; Cancer; Cancer metastasis; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - complications; Complications; Computed tomography; Cryosurgery - methods; Development and progression; Female; Hemoptysis; Humans; Intervals; Laparoscopy; Lung cancer; Lung Neoplasms - mortality; Lung Neoplasms - secondary; Lung Neoplasms - surgery; Male; Medicine; Metastases; Metastasis; Metastatic seeding; Middle Aged; Ostomy; Patients; Permeability; Pleural effusion; Pneumothorax; Safety; Surgery; Survival; Survival Rate; Treatment Outcome; Tumor necrosis factor-TNF; Tumors; Japan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0027086

To evaluate the safety and efficacy of cryoablation for metastatic lung tumors from colorectal cancer. The procedures were performed on 24 patients (36-82 years of age, with a median age of 62; 17 male patients, 7 female patients) for 55 metastatic tumors in the lung, during 30 sessions. The procedural safety, local progression free interval, and overall survival were assessed by follow-up computed tomographic scanning performed every 3-4 months. The major complications were pneumothorax, 19 sessions (63%), pleural effusion, 21 sessions (70%), transient and self-limiting hemoptysis, 13 sessions (43%) and tract seeding, 1 session (3%). The 1- and 3-year local progression free intervals were 90.8% and 59%, respectively. The 3-years local progression free intervals of tumors ≤15 mm in diameter was 79.8% and that of tumors >15 mm was 28.6% (p = 0.001; log-rank test). The 1- and 3-year overall survival rates were 91% and 59.6%, respectively. The results indicated that percutaneous cryoablation is a feasible treatment option. The local progression free interval was satisfactory at least for tumors that were ≤15 mm in diameter.